Diagnostic Efficiency of Magnetic Resonance Spectroscopy and Diffusion Weighted Imaging for Prostate Cancer: A Meta-analysis
10.3969/j.issn.1005-5185.2017.09.020
- VernacularTitle:前列腺癌磁共振波谱与扩散加权成像诊断效能的Meta分析
- Author:
Jiaqi LIU
1
;
Jian JIANG
;
Shunda HONG
;
Fuqing ZHOU
;
Lili GU
;
Xianjun ZENG
Author Information
1. 南昌大学第一附属医院影像科 江西南昌330006
- Keywords:
Prostatic neoplasms;
Magnetic resonance imaging;
Magnetic resonance spectroscopy;
Diffusion-weighted imaging;
Meta-analysis
- From:
Chinese Journal of Medical Imaging
2017;25(9):711-715
- CountryChina
- Language:Chinese
-
Abstract:
Purpose To investigate the diagnostic value of magnetic resonance spectroscopy (MRS) and diffusion weighted imaging (DWI) in diagnosing prostate cancer among Chinese patients.Materials and Methods A Meta-analysis was performed on papers relating to diagnostic value of MRS and DWI in Chinese patients with prostate cancer for the recently ten years using Review Manager 5.2 and Meta-Disc software.QUADAS was employed to assess the quality of qualified articles based on the calculated sensitivity,specificity,diagnostic odds ratio and area under the receiver operating characteristic (ROC) curve of MRS and DWI.Results Ten relevant literatures were enrolled.Heterogeneity of sensitivity and specificity was excluded in accordance to results of Meta-analysis,and hence the combination was feasible.The combination results indicated that AUC of ROC for DWI and MRS were 0.8979 and 0.9302,respectively;sensitivity was 0.83 and 0.87,respectively;specificity was 0.84 and 0.86,respectively;DOR was 22.71 and 41.31,respectively.Conclusion MRS is higher than DWI in terms of diagnostic value of prostate cancer as well as its sensitivity and specificity.When prostate cancer is untypical in DWI findings or not clear in its diagnosis,MRI results can be further consulted.This paper investigated the value of DWI and MRS in diagnosing prostate cancer through quantitative system evaluation,providing evidence-based medicine reference for using imaging methods to diagnose prostate cancer.
